Lilly discontinues Phase III RA trial of tabalumab

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase III FLEX-M trial of tabalumab ( LY2127399) for rheumatoid arthritis after the compound missed efficacy expectations in a planned interim futility analysis. Lilly said it will suspend enrollment in two other Phase III trials and an open-label extension study of tabalumab for RA until interim data from the trials are available early next year. ...